Description
| 0.139 | 30g |
Eflornithine, available under brand names such as Vaniqa, serves as a medication used to address African trypanosomiasis and excessive facial hair growth in women. It is particularly effective for the second stage of sleeping sickness induced by T.b. gambiense and can be combined with nifurtimox.
In the context of women, this drug is employed to decelerate the growth of facial hair, specifically beneath the chin. It is not intended for use on other body areas. Eflornithine functions by obstructing specific natural substances (enzymes) essential for the growth of hair on the skin. This action leads to a reduction in the speed of hair growth, resulting in finer and lighter hair. It is important to note that it does not eliminate hair or induce hair loss. Vaniqa should not be administered to children under the age of 12.
